Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase 2 Bilateral (Split-face) Comparison Study to Assess Two Formulations of ELAPR Compared to Juvéderm® Ultra Plus for the Treatment of Moderate to Severe Nasolabial Folds

Authors not listed

Elastagen Pty Ltd · 2011

Mitochondrial dysfunction Human Randomized controlled trial

Abstract

Patients presenting to the clinic for treatment of moderate to severe Nasolabial folds will be recruited to receive either ELAPR002b or ELAPR002d for the treatment of one Nasolabial fold and Juvéderm® Ultra Plus for the treatment of the second, opposite Nasolabial fold.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-05-29 MST

Cite this

APA

Anonymous. (2011). A Phase 2 Bilateral (Split-face) Comparison Study to Assess Two Formulations of ELAPR Compared to Juvéderm® Ultra Plus for the Treatment of Moderate to Severe Nasolabial Folds. <em>Elastagen Pty Ltd</em>. https://clinicaltrials.gov/study/NCT01463657

Vancouver

Anonymous. A Phase 2 Bilateral (Split-face) Comparison Study to Assess Two Formulations of ELAPR Compared to Juvéderm® Ultra Plus for the Treatment of Moderate to Severe Nasolabial Folds. Elastagen Pty Ltd. 2011.

BibTeX

@misc{anon2011APhase, title = {A Phase 2 Bilateral (Split-face) Comparison Study to Assess Two Formulations of ELAPR Compared to Juvéderm® Ultra Plus for the Treatment of Moderate to Severe Nasolabial Folds}, author = {Anonymous}, journal = {Elastagen Pty Ltd}, year = {2011}, }